In Search of the Perfect Earn-Out
This article was originally published in Start Up
Executive Summary
The widening gap between expectations of pricing between the buyers and sellers of emerging medical technology companies has increased the number of earn-out transactions, all of which have been different and offered varying degrees of risk and reward. According to Richard Ferrari, a managing director of De Novo Ventures, earn-out transactions are complex and need careful consideration to ensure that they benefit both parties--a poorly structured deal can lead to opportunistic behavior by the acquirer. Ferrari discusses the four stages that define the structure of all earnout transactions
You may also be interested in...
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion
Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.